North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma

Robert R. McWilliams, Nathan R. Foster, Michelle R. Mahoney, Thomas C. Smyrk, Joseph A. Murray, Matthew M. Ames, L. Elise Horvath, Daniel J. Schneider, Timothy J. Hobday, Aminah Jatoi, Jeffrey P. Meyers, Matthew P. Goetz

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences